ClinicalTrials.gg
Status unknownNCT01206647Updated Sep 22, 2010

Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Metformin and Saxagliptin in Diabetes Mellitus, Type 2, sponsored by ikfe-CRO GmbH. Status unknown at 7 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-09-22.

Sponsored by ikfe-CRO GmbH · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2010), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Planned enrollment
119th of 287
120 · median 100
Started
2010
with 19 others
Phase 4
98 of 293
6 open now
Registered
114th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 119th largest by planned enrollment of the 287 interventional ones that give a count, is one of 20 that started in 2010, is one of 98 in phase 4, and was the 114th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the success rate of a switch from insulin therapy to a metformin \& saxagliptin combination in patients with type 2 diabetes mellitus.

Read the detailed description

The following study is based on a previous clinical trial performed at ikfe GmbH in Mainz in 2006 and 2007 (PIOswitch). [2] The purpose of this trial was to demonstrate that type 2 diabetes patients treated with insulin can be effectively switched to a pioglitazone/glimepiride combination without loss of glycemic control. The study was performed with 100 patients, out of whom 76 were finally successfully switched, resulting in a cheaper and more convenient therapy with indications of an improved laboratory cardiovascular risk biomarker profile (Hohberg et al., Diabetes Obes. Metab. 11:464-471, 2009). [2] Glimeperide is an agent with unspecific stimulating effect on the ß-cell and is considered to accelerate the progression of the disease while still controlling blood glucose. In addition, it may cause hypoglycemia. The combination of pioglitazone with glimepiride was selected, because pioglitazone requires approx. 5-6 weeks for developing its full anti-diabetic efficacy and an immediate effect on glucose was required to avoid glycemic deterioration.

It is tempting to speculate that the combination of a drug providing ß-cell protection (like saxagliptin) with a drug effectively and rapidly lowering blood glucose through a different mechanism of action (metformin) instead of unspecific ß-cell stimulation would result in an even improved outcome without risk of hypoglycemia. The purpose of this study is to investigate the success rate of a switch from insulin therapy to a metformin \& saxagliptin combination in patients with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Combination of OAD and basal insulin treatment (BOT) or intensified conventional therapy (ICT; > 2 injections of basal and prandial) or conventional insulin therapy (CIT; 1 or 2 injections of basal or biphasic)
  • \< 7.5 %
  • Age: 18-80 years inclusively
  • Duration of insulin therapy > 1 year
  • Insulin dose \< 120 IU/day
  • Fasting C-peptide > 0.6 ng/l
  • Fasting glucose ≤ 210 mg/dl
  • Full legal, mental and physical ability to give
  • Patient consent that the general physician will be informed of trail participation
  • Experience in self measurement of blood glucose > 1 year

Exclusion criteria

Exclusion Criteria:

  • Type 1 Diabetes mellitus
  • History of drug or alcohol abuse within the last five years prior to screening
  • History of severe or multiple allergies
  • Progressive fatal disease
  • History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), neurological, psychiatric and/or haematological disease as judged by the investigator
  • Renal insufficiency or history of significant renal diseases ( lower than 60 ml/min determined using the Cockroft-Goult equation).
  • for study drugs including contraindications for the rescue drugs
  • Anamnestic history of to the study drugs or to drugs with similar chemical structures
  • Pregnancy or breast feeding
  • Sexually active women of not consistently and correctly practicing by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomised partner
  • Treatment with any other drug within 3 months prior to screening
  • Lack of compliance or other similar reason, that according to investigator, precludes satisfactory participation in the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • No intervention
    Control arm

    The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.

  • Experimental
    Saxagliptin & metformin

    Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.

    Drug: Metformin and Saxagliptin

Interventions

  • DrugMetformin and Saxagliptin

    Drug pages: Metformin · Saxagliptin

    Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial

06

What researchers measure

Primary outcomes

  1. percentage of patients with stable HbA1c

    Time frame: 26 ± 2 weeks (baseline to postbaseline values) at 4 week intervals

Secondary outcomes

  1. impact of the switch on:

    - Biomarkers of insulin resistance and ß-cell function

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

  2. impact of the switch on:

    - Biomarkers of cardiovaskular risk

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

  3. impact of the switch on:

    - Patient treatment satifaction

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

  4. impact of the switch on:

    - Treatment costs

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

  5. impact of the switch on:

    - Requirement of 3rd line OAD pioglitazone as rescue drug

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

  6. impact of the switch on:

    - oral Glucose Tolerance Test (oGTT)

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

  7. impact of the switch on:

    - Macrophagen activation (in a subpopulation at site 01 ikfe GmbH)

    Time frame: 26 ± 2 weeks (baseline to postbaseline values)

07

Study locations

7 sites
  • Diabetologische Schwerpunktpraxis Dr. Lorra / Dr. Bonnermann
    Bochum, 44869, Germany
  • Zentrum für klinische Studien Dresden, GWT-TUD GmbH
    Dresden, 01307, Germany
  • Gemeinschaftspraxis Partner der Gesundheit
    Essen, 45355, Germany
  • IKFE Institute for Clinical Research and Development
    Mainz, 55116, Germany
  • Zentrum für Diabetes und Gefäßerkrankungen
    Münster, 48145, Germany
  • Diabetes Zentrum Neuwied
    Neuwied, 56564, Germany
  • ikfe Studiencenter Potsdam GmbH
    Potsdam, 14469, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2010
First posted
Sep 22, 2010
Start
Feb 2010
Primary completionEst.
Feb 2011
CompletionEst.
Feb 2011
Last update
Sep 22, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01206647
Lead sponsor
ikfe-CRO GmbH
Collaborators
AstraZeneca, IKFE Institute for Clinical Research and Development
First posted
Sep 22, 2010
Start date
Feb 2010
Primary completion
Feb 2011 (estimated)
Completion
Feb 2011 (estimated)
Last update
Sep 22, 2010

Study contacts

Andreas Pfützner, Prof.Dr.Dr.
principal investigator · IKFE Institute for Clinical Research and Development

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Saxagliptin

Start the discussion